Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

BACKGROUND: Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)‐antagonist therapy in Crohn's disease (CD). AIM: To compare safety and effectiveness of vedolizumab and TNF‐antagonist therapy in adult CD patients. METHODS: Retrospective observational cohort (May 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Bohm, Matthew, Xu, Ronghui, Zhang, Yiran, Varma, Sashidhar, Fischer, Monika, Kochhar, Gursimran, Boland, Brigid, Singh, Siddharth, Hirten, Robert, Ungaro, Ryan, Shmidt, Eugenia, Lasch, Karen, Jairaith, Vipul, Hudesman, David, Chang, Shannon, Lukin, Dana, Swaminath, Arun, Sands, Bruce E., Colombel, Jean‐Frederic, Kane, Sunanda, Loftus, Edward V., Shen, Bo, Siegel, Corey A., Sandborn, William J., Dulai, Parambir S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Vedolizumab or TNF Antagonists for Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496810/
https://www.ncbi.nlm.nih.gov/pubmed/32656800
http://dx.doi.org/10.1111/apt.15921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496810/
https://www.ncbi.nlm.nih.gov/pubmed/32656800
http://dx.doi.org/10.1111/apt.15921

Ejemplares similares